Two Sigma Advisers
DNA icon

Two Sigma Advisers’s Ginkgo Bioworks DNA Stock Holding History

Two Sigma Advisers’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,856
Closed -$98.5K – 608
2025
Q4 		$98.5K Sell
11,856
-19,252
-62% -$207K ﹤0.01% 2226
2025
Q3 		$454K Sell
31,108
-7,730
-20% -$92.5K ﹤0.01% 1798
2025
Q2 		$437K Sell
38,838
-418,780
-92% -$3.24M ﹤0.01% 1809
2025
Q1 		$2.61M Sell
457,618
-283,500
-38% -$2.89M 0.01% 1049
2024
Q4 		$7.28M Sell
741,118
-66,100
-8% -$567K 0.02% 574
2024
Q3 		$6.58M Buy
807,218
+21,129
+3% +$212K 0.02% 619
2024
Q2 		$10.5M Buy
786,089
+757,813
+2,680% +$22.6M 0.02% 524
2024
Q1 		$1.31M Buy
28,276
+9,452
+50% +$489K ﹤0.01% 1443
2023
Q4 		$1.27M Buy
18,824
+14,705
+357% +$900K ﹤0.01% 1525
2023
Q3 		$298K Sell
4,119
-1,870
-31% -$150K ﹤0.01% 1980
2023
Q2 		$446K Buy
5,989
+533
+10% +$31.6K ﹤0.01% 1852
2023
Q1 		$290K Buy
5,456
+3,477
+176% +$220K ﹤0.01% 2148
2022
Q4 		$134K Buy
+1,979
New +$182K ﹤0.01% 2255

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers's DNA Position: Q1 2026 in Review

Two Sigma Advisers sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 11,856 shares — an estimated $98.5K sold.

Two Sigma Advisers first reported a position in DNA in Q4 2022 and held it in 13 quarters. The position peaked at $10.5M in Q2 2024. 175 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Two Sigma Advisers reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 11,856 Ginkgo Bioworks shares in Q1 2026, an estimated $98.5K.
  • Two Sigma Advisers first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 13 quarters.
  • Two Sigma Advisers's Ginkgo Bioworks position peaked at $10.5M in Q2 2024.
  • 175 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.